William Blair Initiates Coverage On Edgewise Therapeutics with Outperform Rating
Does Edgewise Therapeutics’ (EWTX) HFpEF Expansion Quietly Redefine Its Core Cardiovascular Strategy?
Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
Edgewise Therapeutics Doses First Participant In EQUINOX-HFpEF Study Of EDG-15400 To Treat Adults With Symptomatic Heart Failure With Preserved Ejection Fraction
Edgewise Therapeutics (EWTX) Sets EDG 7500 Focus Call, Is It Still 20% Below Fair Value?
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says
Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript
Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 - Slideshow
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
HC Wainwright & Co. Maintains Buy on Edgewise Therapeutics, Raises Price Target to $57
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
Edgewise Therapeutics: The Servier Deal Creates A Self-Funded Cardiovascular Platform
Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $36
Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
Edgewise Therapeutics Q2 EPS $(0.53) Misses $(0.47) Estimate
Edgewise Therapeutics (EWTX) Trades At A Rich P B, Is The Premium Justified?
Evercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $55
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.